Page last updated: 2024-11-02

pioglitazone and Complications of Diabetes Mellitus

pioglitazone has been researched along with Complications of Diabetes Mellitus in 55 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days."9.19Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014)
"This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects."9.19Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014)
"To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus."9.15Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011)
"This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk."9.15Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011)
"This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)."9.14Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009)
"This article reviews human observations on pioglitazone and bladder cancer risk."8.88Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012)
"The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer."7.91Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019)
" This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model."7.85Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017)
"Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials."7.75Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009)
"Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients."7.74Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007)
" Nevertheless, pioglitazone (when compared to rosiglitazone) was found to have long-term value as a treatment option for T2DM patients with dyslipidemia treated within the US payer setting."7.74Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."7.72Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Pioglitazone (PIO) is a new class of anti-diabetic agent with an anti-inflammatory effect."6.76Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. ( Abe, M; Kasahara, Y; Kataoka, Y; Kokubu, N; Otsuka, Y; Yagi, N, 2011)
"Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone."6.73Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007)
"Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo."6.73Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008)
"Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU."5.43Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016)
" A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days."5.19Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014)
"This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects."5.19Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014)
"To evaluate the efficacy and safety of combination therapy with candesartan cilexetil (CC) and pioglitazone hydrochloride (PIO) in patients with hypertension and type 2 diabetes mellitus."5.15Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. ( Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011)
"This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk."5.15Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011)
"In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity."5.14Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009)
"This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)."5.14Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009)
"This article reviews human observations on pioglitazone and bladder cancer risk."4.88Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012)
" 3041 were excluded, and we did a systematic review and meta-analysis of the seven remaining randomised double-blind clinical trials of drug-related congestive heart failure in patients given TZDs (either rosiglitazone or pioglitazone)."4.84Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. ( Lago, RM; Nesto, RW; Singh, PP, 2007)
"The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer."3.91Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019)
" This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model."3.85Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017)
" Treatment with pioglitazone improved heart function by decreasing the expression of AGEs and OX-62 in the rats with myocardial infarction (MI) plus diabetes."3.80Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells. ( Cao, W; Chen, J; Chen, X; Chen, Y; Liu, P, 2014)
" In this study, we aim to develop a drug-eluting scaffold with a payload of pioglitazone to simultaneously rein in hyperglycemia and recoup lost renal functions in diabetic mice that underwent islet transplantation."3.80A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes. ( Fu, Z; Han, B; He, Q; Tang, K; Xu, J; Yin, H; Zhang, X, 2014)
"Administration of rutin (50 and 100 mg/kg) and pioglitazone (10 mg/kg) orally for 3 weeks treatment significantly improved body weight, reduced plasma glucose and glycosylated hemoglobin, pro-inflammatory cytokines (IL-6 and TNF-alpha), restored the depleted liver antioxidant status and serum lipid profile in high fat diet + streptozotocin induced type 2 diabetic rats."3.80Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. ( Ansari, AA; Naik, SR; Niture, NT, 2014)
"Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone."3.77Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011)
" This utilized a single daily dose of pioglitazone for pediatric patients with severe sepsis and septic shock based upon adult and minimal adolescent data."3.77Optimal study design for pioglitazone in septic pediatric patients. ( Ding, L; Kaplan, J; Sherwin, CM; Spigarelli, MG; Vinks, AA, 2011)
"Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials."3.75Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009)
"Our findings from a large population-based cohort of US seniors are compatible with an increased risk of all-cause mortality and congestive heart failure in patients initiating therapy with rosiglitazone compared with similar patients initiating therapy with pioglitazone."3.74Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. ( Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC, 2008)
" Nevertheless, pioglitazone (when compared to rosiglitazone) was found to have long-term value as a treatment option for T2DM patients with dyslipidemia treated within the US payer setting."3.74Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008)
"Very recent subgroup analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events has shown that pioglitazone reduces the risk of recurrent stroke in type 2 diabetic patients."3.74Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007)
"To determine whether thiazolidinediones cause significant changes in intravascular volume, anemia, or chronic heart failure; to determine which thiazolidinedione, rosiglitazone or pioglitazone, has a greater propensity to cause these adverse effects; and to evaluate thiazolidinedione efficacy in patients with diabetes mellitus and end-stage renal disease who require hemodialysis."3.72Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. ( Allcock, NM; Manley, HJ, 2003)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."3.72Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Pioglitazone (PIO) is a new class of anti-diabetic agent with an anti-inflammatory effect."2.76Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. ( Abe, M; Kasahara, Y; Kataoka, Y; Kokubu, N; Otsuka, Y; Yagi, N, 2011)
"Pioglitazone treatment in non-diabetic patients with CAD was associated with a significantly better coronary endothelial function compared to placebo."2.73Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. ( Höher, M; Hombach, V; Kestler, HA; Koenig, W; Marx, N; Nusser, T; Wöhrle, J, 2008)
"Pioglitazone was also found to increase significantly the apo A1 levels in patients with hyperinsulinemia, but there was no significant increase in patients given both atorvastatin and pioglitazone."2.73Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. ( Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U, 2007)
"Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout."2.61Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019)
"The association between nonalcoholic steatohepatitis and cardiovascular disease is clear, though causality remains to be proven in well-controlled prospective studies."2.52Nonalcoholic fatty liver disease: a systematic review. ( Rinella, ME, 2015)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."2.50Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"Patients with type 2 diabetes mellitus frequently have coexistent dyslipidemia, hypertension, and obesity, and are at risk for microvascular and macrovascular disease complications such as myocardial infarction, stroke, retinopathy, and microalbuminuria."2.42Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. ( Chilton, RJ; Stolar, MW, 2003)
"Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU."1.43Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016)
"Pioglitazone was markedly effective in glycemic control in this case."1.35Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. ( Chen, W; Ebihara, K; Hosoda, K; Ito, J; Iwanishi, M; Kusakabe, T; Masuzaki, H; Nakao, K, 2009)
"Pioglitazone failed to increase adiponectin secretion from either ND or T2D VAT and increased cellular content only in ND VAT."1.35Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. ( Ciaraldi, TP; Henry, RR; Oh, DK; Phillips, SA; Savu, MK, 2008)

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's30 (54.55)29.6817
2010's24 (43.64)24.3611
2020's1 (1.82)2.80

Authors

AuthorsStudies
Lian, J1
Fu, J1
Yamada, T1
Hiraoka, E1
Miyazaki, T1
Sato, J1
Ban, N1
Gao, H1
Li, H1
Li, W1
Shen, X1
Di, B1
Garry, EM1
Buse, JB1
Gokhale, M1
Lund, JL1
Nielsen, ME1
Pate, V1
Stürmer, T1
Evans, PL1
Prior, JA1
Belcher, J1
Hay, CA1
Mallen, CD1
Roddy, E1
Yoshii, H1
Onuma, T1
Yamazaki, T1
Watada, H1
Matsuhisa, M1
Matsumoto, M1
Kitagawa, K2
Kitakaze, M1
Yamasaki, Y2
Kawamori, R2
Cao, W1
Chen, J1
Chen, Y1
Chen, X1
Liu, P1
He, Q1
Zhang, X1
Han, B1
Xu, J1
Tang, K1
Fu, Z1
Yin, H1
Zhang, J1
Huang, X1
Wang, L1
Niture, NT1
Ansari, AA1
Naik, SR1
Liu, B1
Wang, J1
Wang, G1
Herrigel, DJ1
Moss, RA1
Rinella, ME1
Kado, T1
Usui, I1
Tobe, K1
Ou, HT1
Chen, YT1
Liu, YM1
Wu, JS1
Dormandy, JA1
Betteridge, DJ1
Schernthaner, G1
Pirags, V1
Norgren, L1
Phillips, SA1
Ciaraldi, TP1
Oh, DK1
Savu, MK1
Henry, RR1
Hirano, M1
Nakamura, T2
Kitta, Y1
Yano, T1
Kobayashi, T1
Sano, K1
Fujioka, D1
Saito, Y1
Kodama, Y1
Kawabata, K1
Nakamura, K1
Obata, JE1
Kugiyama, K1
Tunis, SL2
Minshall, ME2
St Charles, M2
Pandya, BJ2
Baran, RW2
Sano, H1
Tajima, N1
Winkelmayer, WC1
Setoguchi, S1
Levin, R1
Solomon, DH1
Aoyama, T1
Ikejima, K1
Kon, K1
Okumura, K1
Arai, K1
Watanabe, S1
van der Meer, RW1
Rijzewijk, LJ1
de Jong, HW1
Lamb, HJ1
Lubberink, M1
Romijn, JA1
Bax, JJ1
de Roos, A1
Kamp, O1
Paulus, WJ1
Heine, RJ2
Lammertsma, AA1
Smit, JW1
Diamant, M1
Gropler, RJ1
Dormuth, CR1
Maclure, M1
Carney, G1
Schneeweiss, S1
Bassett, K1
Wright, JM1
Iwanishi, M1
Ebihara, K1
Kusakabe, T1
Chen, W1
Ito, J1
Masuzaki, H1
Hosoda, K1
Nakao, K1
Katakami, N1
Furukado, S1
Nagatsuka, K1
Kashiwagi, A1
Daida, H1
Kaku, K2
Kurra, S1
Siris, E1
Sherwin, CM1
Ding, L1
Kaplan, J1
Spigarelli, MG1
Vinks, AA1
Kataoka, Y1
Yagi, N1
Kokubu, N1
Kasahara, Y1
Abe, M1
Otsuka, Y1
Pfützner, A1
Hanefeld, M1
Dekordi, LA1
Müller, J1
Kleine, I1
Fuchs, W1
Forst, T1
Shinohara, Y1
Enya, K1
Sugiura, K1
Totsuka, N1
Gallagher, AM1
Smeeth, L1
Seabroke, S1
Leufkens, HG1
van Staa, TP1
Tseng, CH1
Yokoi, H1
Suzuki, M1
Odaka, H1
Manley, HJ1
Allcock, NM1
Stolar, MW1
Chilton, RJ1
Prasithsirikul, W1
Bunnag, P1
Fonseca, V1
Jawa, A1
Asnani, S1
Irons, BK1
Greene, RS1
Mazzolini, TA1
Edwards, KL1
Sleeper, RB1
Holleman, F1
Gerdes, VE1
de Vries, JH1
Hoekstra, JB1
Veneman, TF1
Schmitz, OE1
Brock, B1
Rungby, J1
Madsbad, S1
Pathan, AR1
Viswanad, B1
Sonkusare, SK1
Ramarao, P1
Kusuyama, T1
Omura, T1
Nishiya, D1
Enomoto, S1
Matsumoto, R1
Takeuchi, K1
Yoshikawa, J1
Yoshiyama, M1
Mehta, A1
Shah, U1
Parikh, K1
Chag, M1
Baxi, H1
Chandarana, A1
Naik, A2
Shah, K1
Goyal, R1
Yamamoto, E1
Kataoka, K1
Yamashita, T1
Tokutomi, Y1
Dong, YF1
Matsuba, S1
Ogawa, H1
Kim-Mitsuyama, S1
Lago, RM1
Singh, PP1
Nesto, RW1
Wöhrle, J1
Marx, N1
Koenig, W1
Hombach, V1
Kestler, HA1
Höher, M1
Nusser, T1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction[NCT03794518]Phase 3648 participants (Anticipated)Interventional2019-03-31Not yet recruiting
The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495]57 participants (Actual)Interventional2019-05-21Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.)
Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects[NCT04282005]28 participants (Anticipated)Interventional2020-02-13Recruiting
Predictors of Improvement of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery[NCT04059029]200 participants (Anticipated)Observational2016-10-31Enrolling by invitation
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet[NCT03141008]54 participants (Actual)Observational2017-09-15Completed
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993]Phase 34,373 participants (Actual)Interventional2001-05-31Completed
Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318]Phase 450 participants (Actual)Interventional2013-11-30Completed
Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182]Phase 1/Phase 212 participants (Actual)Interventional2011-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Effect of Pioglitazone Area Under the Curve on Changes in IL-6

We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study

Interventionng/ml (Least Squares Mean)
Pioglitazone Hydrochloride-1.4425
Normal Standard CareNA

Evaluate the Safety Profile of Pioglitazone in Patients With Severe Sepsis and Septic Shock as the Number of Hypoglycemic Events

The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days

Interventionevents (Number)
Pioglitazone Hydrochloride0
Normal Standard Care0

Pioglitazone Area Under Curve Estimates by Treatment Group and Route of Administration

Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days

Interventionng*h/ml (Mean)
Pioglitazone Hydrochloride by Mouth5363
Pioglitazone Hydrochloride by Nasogastric Tube1052

Safety Labs - Alanine Aminotransferase (ALT)

ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

InterventionU/L (Median)
Pioglitazone Hydrochloride21.5
Normal Standard Care24.5

Safety Labs - Blood Urea Nitrogen (BUN)

BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

Interventionmg/dl (Median)
Pioglitazone Hydrochloride7.5
Normal Standard Care10

Safety Labs - Creatinine

Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study

Interventionmg/dl (Median)
Pioglitazone Hydrochloride0.72
Normal Standard Care0.415

Reviews

12 reviews available for pioglitazone and Complications of Diabetes Mellitus

ArticleYear
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Bo

2021
Gender-specific risk factors for gout: a systematic review of cohort studies.
    Advances in rheumatology (London, England), 2019, 06-24, Volume: 59, Issue:1

    Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic

2019
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp

2014
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
Nonalcoholic fatty liver disease: a systematic review.
    JAMA, 2015, Jun-09, Volume: 313, Issue:22

    Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Live

2015
[Current evidence-based medicine for early intervention in diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:10

    Topics: Diabetes Complications; Diabetes Mellitus; Diet, Diabetic; Evidence-Based Medicine; Exercise Therapy

2008
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H

2010
Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2012, Volume: 111, Issue:3

    Topics: Bias; Comorbidity; Data Interpretation, Statistical; Diabetes Complications; Epidemiologic Research

2012
[Pioglitazone].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 7

    Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetes Complications; Humans; Hypoglycemic Ag

2011
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:7

    Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima

2003
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Clinical therapeutics, 2003, Volume: 25 Suppl B

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemod

2003
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Pharmacotherapy, 2006, Volume: 26, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; H

2006
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
    Lancet (London, England), 2007, Sep-29, Volume: 370, Issue:9593

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; H

2007

Trials

12 trials available for pioglitazone and Complications of Diabetes Mellitus

ArticleYear
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid

2014
Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients.
    International heart journal, 2014, Volume: 55, Issue:6

    Topics: Aged; Angiotensin II; Atrial Fibrillation; Diabetes Complications; Disease Progression; Double-Blind

2014
Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
    Atherosclerosis, 2009, Volume: 202, Issue:1

    Topics: Adult; Aged; Diabetes Complications; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male;

2009
Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome.
    Atherosclerosis, 2009, Volume: 203, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Calibration; Carotid Stenosis; Diabetes Complications; Diabetes Melli

2009
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi

2009
Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Journal of atherosclerosis and thrombosis, 2010, Nov-27, Volume: 17, Issue:11

    Topics: Adult; Aged; Asian People; Carotid Arteries; Carotid Artery Diseases; Case-Control Studies; Comorbid

2010
Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:8

    Topics: Aged; Creatine Kinase; Diabetes Complications; Female; Follow-Up Studies; Humans; Hypoglycemic Agent

2011
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
    Journal of diabetes science and technology, 2011, Jul-01, Volume: 5, Issue:4

    Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Vessels; Cardiovascular Diseases; Diabetes C

2011
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
    Current medical research and opinion, 2011, Volume: 27 Suppl 3

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complica

2011
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
    Ugeskrift for laeger, 2006, May-01, Volume: 168, Issue:18

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H

2006
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
    Canadian journal of physiology and pharmacology, 2007, Volume: 85, Issue:6

    Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HD

2007
Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2008, Volume: 97, Issue:10

    Topics: Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Endothelium, Vascular; Female;

2008

Other Studies

31 other studies available for pioglitazone and Complications of Diabetes Mellitus

ArticleYear
Diabetes as First Manifestation of Autoimmune Pancreatitis.
    The American journal of the medical sciences, 2017, Volume: 353, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli

2017
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Dec-26, Volume: 23

    Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli

2017
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:9

    Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellit

2019
Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells.
    Applied biochemistry and biotechnology, 2014, Volume: 172, Issue:8

    Topics: Animals; Coculture Techniques; Dendritic Cells; Diabetes Complications; Dose-Response Relationship,

2014
A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes.
    Theranostics, 2014, Volume: 4, Issue:5

    Topics: Animals; Blood Urea Nitrogen; Creatinine; Diabetes Complications; Diabetes Mellitus; Humans; Hypergl

2014
Pioglitazone inhibits the expression of matrix metalloproteinase-9, a protein involved in diabetes-associated wound healing.
    Molecular medicine reports, 2014, Volume: 10, Issue:2

    Topics: Animals; Cattle; Cell Line; Cell Survival; Diabetes Complications; Gene Expression; Glycation End Pr

2014
Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers.
    Indian journal of experimental biology, 2014, Volume: 52, Issue:7

    Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mell

2014
[Pioglitazone and the risk of bladder cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74 Suppl 2

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedi

2016
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
    Diabetes research and clinical practice, 2016, Volume: 116

    Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mel

2016
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue.
    American journal of physiology. Endocrinology and metabolism, 2008, Volume: 295, Issue:4

    Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Cytokines; Diabetes Complications; Diabetes Mellitus

2008
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Current medical research and opinion, 2008, Volume: 24, Issue:11

    Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dise

2008
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Archives of internal medicine, 2008, Nov-24, Volume: 168, Issue:21

    Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents;

2008
Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:5

    Topics: Adipokines; Animals; Blood Glucose; Diabetes Complications; Hepatectomy; Hypoglycemic Agents; Insuli

2009
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A

2009
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    Current medical research and opinion, 2009, Volume: 25, Issue:6

    Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Co

2009
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
    PloS one, 2009, Jun-27, Volume: 4, Issue:6

    Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Femal

2009
Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:12

    Topics: Absorptiometry, Photon; Adiponectin; Adiposity; Blood Glucose; Body Composition; Diabetes Complicati

2009
Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures.
    Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:5

    Topics: Accidental Falls; Bone and Bones; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellit

2011
Optimal study design for pioglitazone in septic pediatric patients.
    Journal of pharmacokinetics and pharmacodynamics, 2011, Volume: 38, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Diabetes

2011
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases

2011
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
    Pharmacotherapy, 2003, Volume: 23, Issue:7

    Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Fem

2003
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:2

    Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch

2004
[Type 2 diabetic as cardiovascular risk patient].
    Krankenpflege Journal, 2005, Volume: 43, Issue:4-6

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age

2005
Commentary: the PROactive study--the glass is half full.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:1

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Hum

2006
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Nederlands tijdschrift voor geneeskunde, 2006, Feb-18, Volume: 150, Issue:7

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine;

2006
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Nederlands tijdschrift voor geneeskunde, 2006, Apr-22, Volume: 150, Issue:16

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine;

2006
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Nederlands tijdschrift voor geneeskunde, 2006, Apr-22, Volume: 150, Issue:16

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine;

2006
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
    Life sciences, 2006, Nov-02, Volume: 79, Issue:23

    Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen

2006
Effects of treatment for diabetes mellitus on circulating vascular progenitor cells.
    Journal of pharmacological sciences, 2006, Volume: 102, Issue:1

    Topics: Actins; Adult; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Complications; Diabetes

2006
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschritte der Medizin, 2007, Aug-02, Volume: 149, Issue:31-32

    Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Th

2007
Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.
    Stroke, 2007, Volume: 38, Issue:11

    Topics: Animals; Blood Glucose; Blood Pressure; Cerebral Arteries; Cytokines; Diabetes Complications; Diseas

2007